Table 3.
Participant characteristics and association with recurrence free survival in IC/RT subgroup
| Characteristic | No. (%)a | Univariate, HR (95% CI) | P Value |
|---|---|---|---|
| Age, year (> 43 vs ≤ 43) | 43.5 vs 56.5 | 1.03 (0.44 to 2.46) | 0.94 |
| Gender (Male vs Female) | 78.3vs 21.7 | 0.82 (0.36 to 1.87) | 0.64 |
| T stage (T1-T2 vs T3-T4) | 10.1vs 89.9 | 2.17 (0.64 to 7.37) | 0.22 |
| N stage (N0-N1 vs N2-N3) | 43.5 vs 56.5 | 1.25 (0.53 to 2.96) | 0.62 |
| Overall stage (III vs IVa) | 46.4 vs 53.6 | 1.06 (0.44 to 2.56) | 0.90 |
| 14-3-3σb (> 7.0 vs ≤ 7.0) | 39.6 vs 60.4 | 0.70 (0.26 to 1.83) | 0.46 |
| AKT1b (> 5.0 vs ≤ 5.0) | 57.8 vs 42.2 | 0.45 (0.18 to 1.10) | 0.08 |
| Aurora-Ab (≤ 7.0 vs > 7.0) | 47.8 vs 52.2 | 2.13 (0.90 to 5.02) | 0.08 |
| Baxb (≤ 3.5 vs > 3.5) | 47.1 vs 52.9 | 0.97 (0.41 to 2.31) | 0.94 |
| Bcl-2b (> 3.5 vs ≤ 3.5) | 43.5 vs 56.5 | 1.06 (0.45 to 2.50) | 0.90 |
| Beclin 1b (≤ 8.0 vs > 8.0) | 55.9 vs 44.1 | 1.37 (0.55 to 3.40) | 0.50 |
| β-cateninb (> 5.0 vs ≤ 5.0) | 70.6 vs 29.4 | 1.53 (0.59 to 3.94) | 0.38 |
| CDC2b (≤ 5.0 vs > 5.0) | 44.9 vs 55.1 | 0.91 (0.39 to 2.15) | 0.83 |
| CD31c (≤ 379.1 vs > 379.1) | 55.6 vs 44.4 | 1.85 (0.62 to 5.52) | 0.27 |
| CD34c (≤ 380.5 vs > 380.5) | 60.9 vs 39.1 | 1.59 (0.53 to 4.77) | 0.40 |
| CENP-Hb (≤ 5.0 vs > 5.0) | 58.8 vs 41.2 | 1.41 (0.60 to 3.32) | 0.43 |
| C-Metb (≤ 5.0 vs > 5.0) | 54.4 vs 45.6 | 2.48 (1.00 to 6.14) | 0.05 |
| COX2b (≤ 5.0 vs > 5.0) | 46.4 vs 53.6 | 1.47 (0.61 to 3.55) | 0.39 |
| Cyclin D1b (≤ 3.5 vs > 3.5) | 49.3 vs 50.7 | 1.41 (0.60 to 3.33) | 0.43 |
| E-Cadherinb (> 3.5 vs ≤ 3.5) | 52.9 vs 47.1 | 0.62 (0.26 to 1.46) | 0.27 |
| ERKb (≤ 5.0 vs > 5.0) | 55.1 vs 44.9 | 1.74 (0.74 to 4.09) | 0.21 |
| EZH2b (≤ 8.5 vs > 8.5) | 50.7 vs 49.3 | 1.14 (0.48 to 2.71) | 0.76 |
| HIF-1αb (≤ 5.0 vs > 5.0) | 55.1 vs 44.9 | 2.49 (1.00 to 6.16) | 0.05 |
| Ki-67b (≤ 5.0 vs > 5.0) | 51.5 vs 48.5 | 1.46 (0.62 to 3.43) | 0.39 |
| LMP1b (> 5.0 vs ≤ 5.0) | 47.4 vs 52.6 | 1.16 (0.46 to 2.96) | 0.75 |
| MMP-2b (≤ 7.0 vs > 7.0) | 50.7 vs 49.3 | 1.63 (0.69 to 3.83) | 0.27 |
| MMP-9b (> 1.5 vs ≤ 1.5) | 53.8 vs 46.2 | 1.02 (0.41 to 2.57) | 0.96 |
| N-Cadherinb (≤ 5.0 vs > 5.0) | 55.2 vs 44.8 | 1.06 (0.45 to 2.49) | 0.90 |
| nm23-H1b (≤ 5.0 vs > 5.0) | 40.7 vs 59.3 | 1.23 (0.52 to 2.89) | 0.64 |
| P21b (≤ 3.5 vs > 3.5) | 44.9 vs 55.1 | 1.80 (0.76 to 4.28) | 0.18 |
| P27b (≤ 7.0 vs > 7.0) | 56.5 vs 43.5 | 1.82 (0.77 to 4.28) | 0.17 |
| p-ERKb (> 2.5 vs ≤ 2.5) | 47.2 vs 52.8 | 0.93 (0.36 to 2.46) | 0.89 |
| Pontinb (> 3.5 vs ≤ 3.5) | 52.3 vs 47.7 | 0.72 (0.31 to 1.69) | 0.45 |
| Snailb (> 3.5 vs ≤ 3.5) | 44.9 vs 55.1 | 0.68 (0.29 to 1.60) | 0.38 |
| Stathminb (≤ 7.0 vs > 7.0) | 53.6 vs 46.4 | 0.85 (0.35 to 2.04) | 0.71 |
| Survivinb (> 2.5 vs ≤ 2.5) | 43.5 vs 56.5 | 0.70 (0.28 to 1.73) | 0.44 |
| TIMP-2b (> 7.0 vs ≤ 7.0) | 46.4 vs 53.6 | 0.94 (0.40 to 2.22) | 0.89 |
| Twistb (> 2.5 vs ≤ 2.5) | 43.3 vs 56.7 | 1.54 (0.64 to 3.73) | 0.34 |
| EA-IgAd (≤ 1:40 vs > 1:40) | 61.2 vs 38.8 | 1.17 (0.45 to 3.05) | 0.75 |
| VCA-IgAd (≤ 1:160 vs > 1:160) | 37.3 vs 62.7 | 1.24 (0.50 to 3.03) | 0.64 |
| AERd (≤ 64.5% vs > 64.5%) | 50.0 vs 50.0 | 2.06 (0.85 to 4.99) | 0.11 |